oncolytic virus + anti-PD1 + chemotherapy

This is a combination therapy consisting of an oncolytic virus, an anti-PD-1 immune checkpoint inhibitor, and chemotherapy. Oncolytic viruses are engineered or naturally occurring viruses that selectively infect and lyse cancer cells while stimulating antitumor immune responses. Anti-PD-1 agents are monoclonal antibodies that block the programmed cell death protein 1 (PD-1) pathway, thereby enhancing T-cell-mediated immune responses against tumors. Chemotherapy involves cytotoxic drugs that kill rapidly dividing cancer cells but can also modulate the tumor microenvironment to enhance viral infectivity and immunogenicity. The rationale for this combination is to harness complementary mechanisms: - Oncolytic viruses directly destroy tumor cells and convert immunologically "cold" tumors into "hot" ones by attracting immune effector cells. - Anti-PD-1 inhibitors release the brakes on T-cells, allowing for a more robust antitumor response. - Chemotherapy can increase tumor cell permeability to viral infection and may synergize with both virotherapy and immunotherapy by reducing tumor burden or altering the microenvironment. Preclinical studies have shown enhanced efficacy when these modalities are combined compared to monotherapies. Clinical trials have explored various combinations of these approaches in solid tumors such as melanoma, lung cancer, pancreatic cancer, glioblastoma, and others[1][2][4].